Extended-spectrum \(\beta\)-lactamase-producing enterobacteriaceae in community-acquired urinary tract infections in São Luís, Brazil

Afonso Gomes Abreu\(^1\), Sirlei Garcia Marques\(^2\), Valério Monteiro-Neto\(^1,3,4\), Azizedite Guedes Gonçalves\(^1,4\)

\(^1\)Universidade Federal do Maranhão, São Luís, MA, Brazil. \(^2\)Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil. \(^3\)Centro Universitário do Maranhão, São Luís, MA, Brazil. \(^4\)Departamento de Patologia, Universidade Federal do Maranhão, São Luís, MA, Brazil.

Submitted: June 3, 2011; Approved: June 5, 2012.

Abstract

The number of ESBL-producing Enterobacteriaceae in community-acquired urinary tract infections worldwide is probably underestimated because of the technical difficulties encountered with their detection. In this study, out of 5,672 urine samples analyzed, 916 were positive for uropathogens, 472 of them being enterobacteria of which 7.6% produced \(\beta\)-lactamases. Analysis of the isolated from 36 patients showed a high level of antibiotic resistance, with 52.7% and 80.5% of isolates expressing \(\text{bla}_{\text{TEM}}\) and \(\text{bla}_{\text{CTX-M}}\), respectively.

Key words: enterobacteriaceae, antimicrobial resistance, ESBL, community-acquired infections.

Beta-lactamases are bacterial enzymes that inactivate \(\beta\)-lactam antibiotics by hydrolysis, which results in ineffective compounds. One group of \(\beta\)-lactamases, extended-spectrum \(\beta\)-lactamases (ESBLs), are able to hydrolyze and cause resistance against a wide variety of novel \(\beta\)-lactams, including third-generation cephalosporins and monobactams, but not against cephemycins and carbapenems (Pitout and Laupland, 2008). ESBLs are common in hospitalized patients (Freitas et al., 2003) and only a few studies have investigated the presence of these bacteria in community patients, especially urine cultures (Minarini et al., 2007). The aim of the present study was to detect \(\text{bla}_{\text{TEM}}\) and \(\text{bla}_{\text{CTX-M}}\) genes by molecular methods in enterobacteria isolated from urine cultures of patients with community-acquired urinary infection and analyze their antimicrobial susceptibility profile.

A total of 5,672 consecutive urines samples were collected from a private diagnostic laboratory located in São Luis, Brazil between March and August, 2009. Of these, 916 were positive uropathogens, including 472 (51.5%) enterobacteria. Susceptibility testing was performed and interpreted by disk diffusion method (CLSI, 2008) and Vitrek 2 automated system (BioMérieux®, Marcy l’Etoile, France) for all enterobacteria.

The test was run against the following antibiotics: amoxicillin-clavulanic acid (AMC); aztreonam (AZT); ampicillin (AMP); ampicillin-sulbactam (SAM); amikacin (AMK); gentamicin (GEN); cefepime (CFP); cefotaxime (CFX); ceftriaxone (CTX); ciprofloxacín (CIP); levofloxacín (LVX); nitrofuranotín (NIT); piperacillin-tazobactam (TZP); trimethoprim-sulfamethoxazole (SXT); imipenem (IPM); meropenem (MEM); ertapenem (ERT). Pseudomonas aeruginosa ATCC 27853 and E. coli ATCC 25922 and ATCC 35218 were used as quality controls for antimicrobial susceptibility.

ESBL production was analyzed phenotypically by the combination disk method (CLSI, 2008). For confirmation of ESBLs production, the isolates were interpreted by the disk approximation method and addition of clavulanic acid using cefotaxime/clavulanic acid and ceftazidime/clavulanic acid disks. Klebsiella pneumoniae ATCC 700603 and E. coli ATCC 25922 were used as positive and negative controls, respectively. Triplex PCR was used to determine the presence of \(\text{bla}_{\text{TEM}}\) and \(\text{bla}_{\text{CTX-M}}\) genes in ESBLs-
producing Enterobacteriaceae isolates (Monstein et al., 2007).

The prevalence of ESBL-producing Enterobacteriaceae in community-acquired urinary infections in southern Brazil is 1.5% (Minarini et al., 2007), 3.5% in Italy (Luzzaro et al., 2006) and 4.5% in Saudi Arabia (Khanfar et al., 2009). In this study, 7.6% (36/472) of the enterobacteria isolates were ESBL-s-producers according to the phenotypic methods, demonstrating that the frequency of bacteria expressing the ESBL phenotype significantly varies from region to region. Other studies investigating the production of ESBLs in E. coli isolates also demonstrated the presence of this microorganism in the community (Calbo et al., 2006; Ho et al., 2007; Pitout et al., 2009; Ruppé et al., 2009).

All isolates ESBL-s-producing were resistant to ampicillin, ampicillin-sulbactam, cephalosporins, and aztreonam. With the exception of E. coli, all the others microorganisms showed 100% resistance to ciprofloxacin, levofloxacin and nitrofurantoin, in addition to high resistance to gentamicin, trimethoprim-sulfamethoxazole and piperacillin-tazobactam (Table 1). Amikacin, imipenem, meropenem and ertapenem were the most effective antibiotics against the ESBL-producing strains.

Of the isolates, 97.2% (35/36) carried at least one of the genes investigated by PCR (Table 2). The frequency of the $bla_{TEM}$ gene was 52.7% (19/36), whereas frequencies of 95% and 1% have been reported in studies conducted in southern Brazil (Minarini et al., 2007) and Spain (Rodrigues-Baño et al., 2010). The $bla_{CTX-M}$ gene was detected in 80.5% (29/36) of the isolates and the simultaneous presence of the $bla_{TEM}$ and $bla_{CTX-M}$ genes was demonstrated in 36.1% (13/36) (Table 2). Although TEM and SHV type ESBLs are mainly identified in hospitalized patients, a growing number of community-acquired infections caused by CTX-M-producing species have been recently reported, especially the ones caused by E. coli (Ho et al., 2007; Pitout et al., 2005). In addition to this specie, the present results show that the $bla_{CTX-M}$ gene had high frequency in all isolates, except for Enterobacter cloacae. A significant prevalence of CTX-M-producing species among strains isolated from community patients has been reported in other studies conducted in Brazil (Minarini et al., 2007), Cambodia (Ruppé et al., 2009), Canada (Pitout et al., 2004), France (Arpin et al., 2005) and Italy (Luzzaro et al., 2006).

This is the first study to detect the presence of ESBL-producing Enterobacteriaceae in community-acquired urinary infections in São Luís, Brazil. The results demonstrate that other enterobacteria species produce ESBLs, such as Enterobacter aerogenes, E. cloacae and Morganella morganii (Table 1). This indicates the need to expand the phenotypic methods for these pathogens. Currently, these methods are standardized by the CLSI only for E. coli, K. pneumoniae, K. oxytoca and P. mirabilis. Given this lack of standardized phenotypic methods for detection of ESBLs for all enterobacteria, this study will contribute to a better understanding of the susceptibility of these pathogens.

Our data confirm that carbapenems remain active against these microorganisms. E. coli was the prevalent specie in the ESBL-producing strains isolated from urine.

Table 1 - Antimicrobial resistance profile of the different ESBL-producing species.

| Species          | No. of isolates | AMP | SAM | AMK | GEN | CIP | LVX | NIT | PTZ | SXT | IPM | MEM | ERT |
|------------------|-----------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| E. coli          | 20              | 100.0 | 100.0 | 6.6 | 16.7 | 72.3 | 80.0 | 35.0 | 11.2 | 89.9 | 0.0 | 0.0 | 0.0 |
| K. pneumoniae    | 10              | 100.0 | 100.0 | 10.0 | 70.0 | 100.0 | 100.0 | 100.0 | 60.0 | 90.0 | 10.0 | 0.0 | 0.0 |
| E. cloacae       | 3               | 100.0 | 100.0 | 25.0 | 75.0 | 100.0 | 100.0 | 100.0 | 75.0 | 75.0 | 0.0 | 0.0 | 0.0 |
| E. aerogenes     | 1               | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 0.0 | 0.0 | 0.0 |
| P. mirabilis     | 1               | 100.0 | 100.0 | 0.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 0.0 | 0.0 | 0.0 |
| M. morganii      | 1               | 100.0 | 100.0 | 0.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 0.0 | 0.0 | 0.0 |

AMP: ampicillin; SAM: ampicillin-sulbactam; AMK: amikacin; GEN: gentamicin; CIP: ciprofloxacin; LVX: levofloxacin. NIT: nitrofurantoin; TZP: piperacillin-tazobactam; SXT: trimethoprim-sulfamethoxazole; IPM: imipenem; MEM: meropenem. ERT: ertapenem.

Table 2 - Detection of ESBL-coding genes by PCR according to species.

| Species          | No. isolates | $bla_{TEM}$ | $bla_{CTX-M}$ |
|------------------|--------------|-------------|---------------|
| E. coli          | 3            | +           | -             |
| K. pneumoniae    | 13           | -           | +             |
| K. pneumoniae    | 3            | +           | -             |
| K. pneumoniae    | 1            | -           | -             |
| E. cloacae       | 6            | +           | +             |
| E. aerogenes     | 2            | +           | -             |
| P. mirabilis     | 2            | +           | +             |
| M. morganii      | 1            | +           | +             |
| Total            | 36           | 19 (52.7%)  | 29 (80.5%)    |
culture of community patients and CTX-M the most frequent enzyme.

In summary, although clinicians need to be aware of the presence of ESBLs-producing Enterobacteriaceae in the community, public health control measures are needed to prevent the further spread of these pathogens.

Acknowledgments

We would like to thank the Cedro Laboratory for supplying the isolates and Dr Libera Maria Dalla Costa from the Laboratory of Bacteriology, Federal University of Paraná, Brazil, for providing controls TEM and CTX ESBL-producing *E. coli*. This study was supported by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES / Brazil) and approved by the Ethics Committee of Maranhão Federal University, according to the requirements of the Ministry of Health.

References

Arpin C, Dubois V, Maugein J, Jullin J, Dutilh B, Brochet JP, Larribet G, Fischer I, Quentin C (2005) Clinical and molecular analysis of extended-spectrum β-lactamase-producing enterobacteria in the community setting. J Clin Microbiol 43:5048-5054.

Calbo E, Romani V, Xercavins M, Gómes L, Vidal CG, Quintana S, Vila J, Garau J (2006) Risk factors for community-onset urinary tract infections due to *Escherichia coli* harbouring extended-spectrum β-lactamases. J Antimicrob Chemother 57:780-783.

Clinical and Laboratory Standards Institute (2008) Performance standards for antimicrobial susceptibility testing – Approved standard: 18th informational supplement (M100-S18), CLSI, Wayne.

Freitas ALP, Machado DP, Soares FSC, Barth AL (2003) Extended-Spectrum β-lactamases in *Klebsiella* spp. and *Escherichia coli* obtained in a Brazilian teaching Hospital: Detection, prevalence and molecular typing. Braz J Microbiol 34:344-348.

Ho PL, Poon WWN, Leung MST, Chow KH, Wong RC, Yip KS, Lai EL, Tsang KW (2007) Community emergence of CTX-M type extended-spectrum β-lactamase among urinary *Escherichia coli* from women. J Antimicrob Chemother 60:140-144.

Khanfar HS, Bindayna KM, Senok AC, Botta GA (2009) Extended-spectrum beta-lactamases (ESBLs) in *Escherichia coli* and *Klebsiella pneumoniae*: Trends in the hospital and community settings. J Infect Dev Ctries 3:295-299.

Luzzaro F, Mezzatesta M, Magnioli C, Perilli M, Stefani S, Amicosante G, Rossolini GM, Toniolo A (2006) Trends in production of extended-spectrum β-lactamases among enterobacteria of medical interest: Report of the second Italian nationwide survey. J Clin Microbiol 44:1659-1664.

Minarini LAR, Gales AC, Palazzo ICV, Darini ALC (2007) Prevalence of community-occurring extended spectrum β-lactamase-producing enterobacteriaceae in Brazil. Curr Microbiol 54:335-341.

Monstein HJ, Östholm-Balkhed A, Nilsson NV, Nilsson M, Dornbusch K, Nilsson LE (2007) Multiplex PCR amplification assay for rapid detection of β*SHV*, β*TEM* and β*CTX-M* genes in Enterobacteriaceae. APMIS 115:1400-1408.

Pitout JDD, Hanson ND, Church DL, Laupland KB (2004) Population-based laboratory surveillance for *Escherichia coli*-producing extended-spectrum β-lactamases: The importance of community isolates with blaCTX-M genes. Clin Infect Dis 38:1736-1741.

Pitout JDD, Nordmann P, Laupland LK, Poirier L (2005) Emergence of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs) in the community. J Antimicrob Chemother 56:52-59.

Pitout JDD, Laupland KB (2008) Extended-spectrum β-lactamase-producing Enterobacteriaceae: An emerging public-health concern. Lancet Infect Dis 8:159-166.

Pitout JDD, Gregson DB, Campbell L, Laupland LB (2009) Molecular characteristics of extended-spectrum β-lactamase-producing *Escherichia coli* isolates causing bacteremia in the Calgary health region from 2000 to 2007: Emergence of clone ST131 as a cause of community-acquired infections. Antimicrob Agents Ch 53:2846-2851.

Rodríguez-Baño J, Picón E, Gijón P, Hernández JR, Ruiz M, Peña C, Almela M, Almirante B, Grill F, Colomina A, Giménez M, Oliver A, Horcajada JP, Navarro-Garcia F, Coloma A, Pasqual A (2010) Community-onset bacteremia due to extended-spectrum β-lactamase-producing *Escherichia coli*: Risk factors and prognosis. Clin Infect Dis 50:40-48.

Ruppé E, Hem S, Lath S, Gautier V, Ariey F, Sarthou JL, Monchy D, Arlet G (2009) CTX-M β-lactamases in *Escherichia coli* from community-acquired urinary tract infections, Cambodia. Emerg Infect Dis 15:741-748.

All the content of the journal, except where otherwise noted, is licensed under a Creative Commons License CC BY-NC.